Peripheral T-cell Lymphomas

Blood Reviews

Volumn 21, Issue 4, 2007, Pages 201-216

  Savage, Kerry J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Peripheral T cell lymphomas; Prognosis; Treatment

Indexed keywords

5 F 11; ALEMTUZUMAB; CD30 ANTIGEN; CLUSTERIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GLYCOPROTEIN P; GRANZYME B; LYMPHOCYTE ANTIGEN; MDX 060; MONOCLONAL ANTIBODY; NELARABINE; PERFORIN; PREDNISONE; PROTEIN TYROSINE KINASE; SGN 30; UNCLASSIFIED DRUG; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPLASTIC LARGE CELL LYMPHOMA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CANCER REGRESSION; CLINICAL FEATURE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT OUTCOME;

GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE-CELL; LYMPHOMA, T-CELL, PERIPHERAL; PROGNOSIS;

EID: 34249935172     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2007.03.001     Document Type: Article

References (74)

1. Jaffe E.S., Harris N.L., Stein H., and Vardiman J. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification: Tumours of Hematopoetic and lymphoid Tissues (2001), IARC Prsss, Lyon
2. Savage K.J. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program (2005) 267-277
3. Kwak L.W., Wilson M., Weiss L.M., Doggett R., Dorfman R.F., Warnke R.A., et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol 9 8 (1991) 1426-1431
4. Melnyk A., Rodriguez A., Pugh W.C., and Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89 12 (1997) 4514-4520
5. Gisselbrecht C., Gaulard P., Lepage E., Coiffier B., Briere J., Haioun C., et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92 1 (1998) 76-82
6. Morabito F., Gallamini A., Stelitano C., Callea V., Guglielmi C., Neri S., et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer 101 7 (2004) 1601-1608 Oct 1
7. Savage K.J., Chhanabhai M., Gascoyne R.D., and Connors J.M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15 10 (2004) 1467-1475 Oct
8. Lopez-Guillermo A., Cid J., Salar A., Lopez A., Montalban C., Castrillo J.M., et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology 9 8 (1998) 849-855
9. Gallamini A., Stelitano C., Calvi R., Bellei M., Mattei D., Vitolo U., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood Nov 26 (2003)
10. Mason D.Y., Bastard C., Rimokh R., Dastugue N., Huret J.L., Kristoffersson U., et al. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. see comments. Br J Haematol 74 2 (1990) 161-168
11. Banks P.M., and Warnke R.A. Mature T-cell and NK-cell neoplasms. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues (2001), IARC Prsss, Lyon 189-230
12. Nascimento A.F., Pinkus J.L., and Pinkus G.S. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol 121 5 (2004) 709-717 May
13. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909-18.
14. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K., Shapiro D.N., Look A.T., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non- Hodgkin's lymphoma [letter]. Science 267 5196 (1995) 316-317
15. ten Berge R.L., Oudejans J.J., Ossenkoppele G.J., Pulford K., Willemze R., Falini B., et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. see comments. J Clin Pathol 53 6 (2000) 445-450
16. Gascoyne R.D., Aoun P., Wu D., Chhanabhai M., Skinnider B.F., Greiner T.C., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93 11 (1999) 3913-3921
17. Falini B., Pileri S., Zinzani P.L., Carbone A., Zagonel V., Wolf-Peeters C., et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93 8 (1999) 2697-2706
18. Kwong Y.L. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19 12 (2005) 2186-2194 Dec
19. Attygalle A., Al-Jehani R., Diss T.C., Munson P., Liu H., Du M.Q., et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99 2 (2002) 627-633 Jan 15
20. Dupuis J., Boye K., Martin N., Copie-Bergman C., Plonquet A., Fabiani B., et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30 4 (2006) 490-494 Apr
21. Grogg K.L., Attygale A.D., Macon W.R., Remstein E.D., Kurtin P.J., and Dogan A. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 19 8 (2006) 1101-1107 Aug
22. Dogan A., Attygalle A.D., and Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 121 5 (2003) 681-691 Jun
23. Jaffe E.S., and Railfkiaer E. Mature T-cell and NK neoplasms: Introduction. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues (2001), IARC Press, Lyon 191-194
24. Belhadj K., Reyes F., Farcet J.P., Tilly H., Bastard C., Angonin R., et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102 13 (2003) 4261-4269 Dec 15
25. Toro J.R., Liewehr D.J., Pabby N., Sorbara L., Raffeld M., Steinberg S.M., et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101 9 (2003) 3407-3412 May 1
26. Wang H., Medeiros L.J., and Jones D. Subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma 3 3 (2002) 181-183 Dec
27. Shipp M., Harrington D., Chairpersons, Anderson J., Armitage J., Bonadonna G., et al. A predictive model for aggressive non-Hodgkin's lymphoma: The International NHL Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
28. ten Berge R.L., Oudejans J.J., Ossenkoppele G.J., and Meijer C.J. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review. J Pathol 200 1 (2003) 4-15 May
29. Chim C.S., Ma S.Y., Au W.Y., Choy C., Lie A.K., Liang R., et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103 1 (2004) 216-221 Jan 1
30. Ishida T., Inagaki H., Utsunomiya A., Takatsuka Y., Komatsu H., Iida S., et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10 16 (2004) 5494-5500 Aug 15
31. Tsuchiya T., Ohshima K., Karube K., Yamaguchi T., Suefuji H., Hamasaki M., et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 103 1 (2004) 236-241 Jan 1
32. Niwa R., Shoji-Hosaka E., Sakurada M., Shinkawa T., Uchida K., Nakamura K., et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64 6 (2004) 2127-2133 Mar 15
33. Suzuki R., Kagami Y., Takeuchi K., Kami M., Okamoto M., Ichinohasama R., et al. Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype [In Process Citation]. Blood 96 9 (2000) 2993-3000
34. Schlette E.J., Medeiros L.J., Goy A., Lai R., and Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22 9 (2004) 1682-1688 May 1
35. ten Berge R.L., Meijer C.J., Dukers D.F., Kummer J.A., Bladergroen B.A., Vos W., et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99 12 (2002) 4540-4546 Jun 15
36. Martinez-Delgado B., Melendez B., Cuadros M., Alvarez J., Castrillo J.M., Ruiz De La Parte A., et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 10 15 (2004) 4971-4982 Aug 1
37. Martinez-Delgado B., Cuadros M., Honrado E., Ruiz de la Parte A., Roncador G., Alves J., et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 19 12 (2005) 2254-2263 Dec
38. Ballester B., Gisselbrecht C., Gaulard P., Houlgatte R., and Xerri L. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Annals of Oncology 16 Supp 5 (2005) 124a
39. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 14 (1993) 1002-1006 Apr 8
40. Pfreundschuh M., Trumper L., Kloess M., Schmits R., Feller A.C., Rudolph C., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104 3 (2004) 626-633 Aug 1
41. Pfreundschuh M., Trumper L., Kloess M., Schmits R., Feller A.C., Rube C., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 3 (2004) 634-641 Aug 1
42. Escalon M.P., Liu N.S., Yang Y., Hess M., Walker P.L., Smith T.L., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 103 10 (2005) 2091-2098 May 15
43. Klimecki W.T., Futscher B.W., Grogan T.M., and Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83 9 (1994) 2451-2458 May 1
44. Vose J. The International PTCL Project Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. Session Type: Oral Session. Blood 106 11 (2005) 811a
45. Chim C.S., Chan A.C., and Raymond L. Primary CD30-positive anaplastic large cell lymphoma of the lip. Oral Oncol 34 4 (1998) 313-315
46. Cheung M.M., Chan J.K., Lau W.H., Ngan R.K., and Foo W.W. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54 1 (2002) 182-190 Sep 1
47. You J.Y., Chi K.H., Yang M.H., Chen C.C., Ho C.H., Chau W.K., et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 15 4 (2004) 618-625 Apr
48. Li Y.X., Yao B., Jin J., Wang W.H., Liu Y.P., Song Y.W., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24 1 (2006) 181-189 Jan 1
49. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 10 (2005) 3768-3785 May 15
50. Rodriguez J., Caballero M.D., Gutierrez A., Marin J., Lahuerta J.J., Sureda A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14 12 (2003) 1768-1775 Dec
51. Blystad A.K., Enblad G., Kvaloy S., Berglund A., Delabie J., Holte H., et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27 7 (2001) 711-716 Apr
52. Corradini P., Tarella C., Zallio F., Dodero A., Zanni M., Valagussa P., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20 9 (2006) 1533-1538 Sep
53. Rodriguez J., Caballero M.D., Gutierrez A., Gandarillas M., Sierra J., Lopez-Guillermo A., et al. Autologous Stem Cell Transplantation in Induction Failure Patients with Peripheral T-cell Lymphoma: The GEL/TAMO Experience. Blood 102 11 (2003) 2710a
54. Reimer P., Schertlin T., Rudiger T., Geissinger E., Roth S., Kunzmann V., et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 5 4 (2004) 304-311
55. Reimer P, Rudiger T, Schertlin E, Weissinger F, Einsele H, K. M-HH, et al. Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-cell Lymphomas. A Prospective Multicenter Study. Blood 2005;106(11):2074a.
56. Gisselbrecht C., Lepage E., Molina T., Quesnel B., Fillet G., Lederlin P., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20 10 (2002) 2472-2479 May 15
57. Mounier N., Gisselbrecht C., Briere J., Haioun C., Feugier P., Offner F., et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15 12 (2004) 1790-1797 Dec
58. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 333 23 (1995) 1540-1545 Dec 7
59. Kewalramani T., Zelenetz A.D., Teruya-Feldstein J., Hamlin P., Yahalom J., Horwitz S., et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134 2 (2006) 202-207 Jul
60. Jagasia M., Morgan D., Goodman S., Hamilton K., Kinney M., Shyr Y., et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45 11 (2004) 2261-2267 Nov
61. Song K.W., Mollee P., Keating A., and Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 120 6 (2003) 978-985 Mar
62. Corradini P., Dodero A., Zallio F., Caracciolo D., Casini M., Bregni M., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 11 (2004) 2172-2176 Jun 1
63. Sallah S., Wan J.Y., and Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113 1 (2001) 185-187 Apr
64. Dang N.H., Pro B., Hagemeister F.B., Jones D., Samuels B., Rodriguez M.A., et al. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relpased/Refractory T-cell non-Hodkin's Lympoma. Blood 104 11 (2004) 2641a
65. Piekarz RL, Frye R, Turner M, Wright J, Allen LS, Smith S, et al. Responses and Molecular markers in patients with peripheral t-cell lymphoma treated on a phase II trial of depsipeptide, FK228. 2005;(3061a).
66. Enblad G., Hagberg H., Erlanson M., Lundin J., MacDonald A.P., Repp R., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103 8 (2004) 2920-2924 Apr 15
67. Weidmann E., Hess G., Krause S.W., Hebart H., Dreyling M., Subklewe M., et al. Combination chemo-immunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin is an effective first-line regimen in peripheral T-cell lymphoma. Blood 104 11 (2004) 2640a
68. Rodig S.J., Savage K.J., LaCasce A.S., Weng A.P., Harris N.L., Shipp M.A., et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 31 1 (2007) 106-112 Jan
69. Forero-Torres A., Bernstein S., Gopal A., Foss F., Leonard J., Rosenblatt J., et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood 104 11 (2004) 2637a
70. Ansell S.M., Byrd J.C., Horwitz S.M., Borchmann P., Engert A., Stair R., et al. Phase I/II Open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lypmphoma. Blood 104 104 (2004) 2636a
71. Passoni L., and Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma 44 10 (2003) 1675-1681 Oct
72. Mounier N., Simon D., Haioun C., Gaulard P., and Gisselbrecht C. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 20 5 (2002) 1426-1427 Mar 1
73. Czuczman M.S., Porcu P., Johnson J., Niedzwiecki D., Canellos G., and Cheson B.D. CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL. Blood 104 11 (2004) 2486a
74. Armitage J.O., Vose J.M., and Weisenburger D.D. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 15 10 (2004) 1447-1449 Oct